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Background/aim: Diagnosing and managing functional mitral regurgitation (MR) is often challenging and requires an integrated
approach including a comprehensive echocardiographic examination. However, the effects of volume overload on the echocardiographic
assessment of MR severity are uncertain. The purpose of this study was to weigh the effects of volume overload in the echocardiographic
assessment of MR severity among patients with heart failure (HF).
Materials and methods: Twenty-nine patients with decompensated HF, who had moderate or severe MR, were included in the present
study. The volume status and the N-terminal pro-B-type natriuretic peptide (proBNP) levels were recorded and the echocardiographic
parameters were assessed. After the conventional treatment for HF, the proBNP levels and the echocardiographic parameters were
assessed again.
Results: The mean age of the patients was 72 ± 9 years and the average hospitalization time was 10.9 ± 5.9 days. Between the beginning
and the end of the treatment, there were significant reductions in the effective regurgitant orifice area (EROA) (0.36 ± 0.09 cm2 to 0.29 ±
0.09 cm2, P < 0.001), vena contracta (VC) (P < 0.001), the regurgitant volume (RV) (P < 0.001), and systolic pulmonary artery pressure
(sPAP) (P < 0.001).
Conclusion: This is the first study to investigate the relationship of changes in severity of MR with volume-load by monitoring the
proBNP levels among patients with HF. The present results demonstrated that volume reduction, as evidenced by a decline in the
proBNP levels, was accompanied by a marked reduction in the EROA, VC, and the RV among patients with left ventricular dysfunction.
Key words: Functional mitral regurgitation, BNP, volume overload, heart failure, echocardiography

1. Introduction
Functional mitral regurgitation (MR) occurs in
approximately one-third to one-half of patients with
cardiomyopathy and contributes to the progression of
ventricular dysfunction [1,2].
The presence of functional MR also serves as a marker
of worse outcomes in patients with heart failure (HF).
Without intervention, survival rates at five years were
about 40% in those with moderate or severe MR [2].
Current guidelines provide detailed recommendations for
the treatment of patients with MR in HF, including cardiac
resynchronization therapy and mitral valve surgery [3,4].
Recently interventional approaches to MR in patients with
left ventricular dysfunction have shown to have a potential
role [5]. Use of these invasive procedures in such cases

confers a significant operational risk and cost; therefore,
precise evaluation of secondary MR severity is quite
important.
The severity assessment of MR is often made based
on echocardiographic criteria. The integration of multiple
parameters, including vena contracta width (VC), the
effective regurgitant orifice area (EROA), the regurgitant
volume (RV), and adjunctive signs are important for
accurate assessment of MR severity [6]. Although
functional MR is dynamic in nature [7,8], the effects of
volume overload on MR severity quantitation have been
less clearly identified.
B-type natriuretic peptide (BNP) is a cardiac
neurohormone synthesized in the cardiac ventricles as a
result of increased wall stress. Diastolic stretch induces
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cardiomyocyte proBNP expression in volume-loaded
conditions such as MR [9–11]. Furthermore, serum
proBNP has been suggested to be an indicator of preload
[12]. In the present study, therefore, we monitored the
serum proBNP levels as a marker of preload and we
aimed to describe the effects of volume overload in the
echocardiographic assessment of MR severity among
patients with HF.
2. Materials and methods
2.1. Study population
Twenty-nine patients with decompensated HF who had
moderate or severe MR were included in the present
prospective study between January 2016 and June 2016.
The study protocol was approved by our local institutional
ethics committee and all participants provided informed
written consents. The exclusion criteria of the study
were as follows: poor image quality, recent myocardial
infarction (within three months), structural mitral valve
abnormalities including mitral valve repair or replacement
history, moderate or severe aortic valve disease, coronary
revascularization schedule, hypertrophic cardiomyopathy,
primary pulmonary hypertension, and intracardiac shunts.
All included subjects who were hospitalized for
decompensated HF were consecutively enrolled. Baseline
clinical information including echocardiographic
parameters, volume status, and proBNP levels were
recorded. All participants received a continuous
intravenous infusion of furosemide during their hospital
stay. After the conventional treatment for HF, proBNP
levels and the echocardiographic parameters were again
assessed on the day of discharge. Follow-up vital status
information was conducted.
2.2. Echocardiographic analysis
Blood pressures were measured using an appropriate cuff
in all cases before the echocardiographic examination, and
if their systolic blood pressure (SBP) was ≥140 mmHg
or diastolic blood pressure (DBP) ≥90 mmHg, captopril
was orally administered in order to control the blood
pressure. After the regulation of blood pressure, the
echocardiographic evaluation was assessed.
Echocardiography was performed using a commercially
available instrument (Vivid 7® GE Medical System, Horten,
Norway) with a 2.5-MHz transducer by an experienced
echocardiography specialist, who was blinded to all
patients. All images were stored for subsequent analysis
and then a single, blinded observer performed offline
analysis. To determine intraobserver variability, stored
images of 15 randomly selected patients were reanalyzed
one month later by the same observer.
All patients underwent a comprehensive M-mode,
two-dimensional (2D), and color Doppler study. When
the patients were in sinus rhythm, three cardiac cycles

were averaged for all measurements. For patients in
atrial fibrillation, five cardiac cycles were averaged. Left
ventricular dimensions were assessed from parasternal
long-axis views using two-dimensional-guided M-mode
with the leading-edge method at end-diastole and -systole.
The left ventricular ejection fraction was calculated by the
modified Simpson’s rule as recommended by the European
Association of Cardiovascular Imaging [13]. The MR was
graded quantitatively in an integrative fashion calculating
VC, EROA, and RV as described in the guidelines [4,14].
The VC width was imaged in multiple views perpendicular
to the commissural line to obtain the largest regurgitant
jet size, and the width of the narrowest portion of the jet
was then measured [15]. The EROA was obtained using
the proximal isovelocity surface area (PISA) method
through color flow mapping in patients with central MR
jets. However, in the case of eccentric or multiple MR jets,
EROA calculation was made using the pulsed wave Doppler
method. The RV was estimated as EROA multiplied by
the velocity time integral of the regurgitant jet [16]. The
systolic pressure gradient peak from the right ventricle to
the right atrium was assessed using a simplified Bernoulli
equation and then the right atrium pressure was added to
obtain the sPAP [13].
2.3. Statistical analysis
The SPSS 22.0 (IBM Corporation, Armonk, NY, USA)
software package was used for statistical analysis.
Categorical variables are presented as number and
percentage. Continuous variables with normal distribution
are presented as mean ± SD; non-normal variables are
reported as median. The Shapiro-Wilk test was used to
determine the normality of distribution of datasets. The
mean comparison of parameters before and after heart
failure treatment were done with Wilcoxon signed-rank
test. And the mean comparison of parameters between
patients received inotropic treatment or not were done
with Mann-Whitney U test. The relationship between two
quantitative variables was analyzed using Spearman’s test.
The frequencies of categorical variables were compared
using Pearson χ2 test, when appropriate. A P-value <0.05
was considered statistically significant. Intraobserver
variability was evaluated by means of the intra-class
correlation coefficient.
3. Results
The baseline characteristics of the patients are shown in
Table 1. The mean age of the patients was 72 ± 9 (range,
52–87) years, and 48.2% were male. The average length
of the hospital stay was 10.9 ± 5.9 days. At the beginning
of hospitalization, continuous IV inotrope was used as a
bridge to standard medical therapy in 14 patients (48.2%).
Dobutamine was ordered at 5–15 mcg/kg/min for nine of
these patients, and dopamine was ordered at a moderate
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Table 1. Baseline characteristics of the patients.
Parameters

Patients (n = 29)

Age (years)

72 ± 9

Males

14 (48.2%)

Body mass index (kg/m2)

30.8 ± 5.2

Hypertension

20 (68.9%)

Coronary artery disease

16 (55.1%)

Diabetes mellitus

9 (31%)

Atrial fibrillation

10 (34.4%)

Hyperlipidemia

11 (37.9%)

Smoking

8 (27.5%)

Systolic blood pressure, mmHg

112.9 ± 12.3

Diastolic blood pressure, mmHg

67.3 ± 5.4

Heart rate, per minute

94.3 ± 16.8

Type of mitral regurgitation jet
Central

23 (79.3%)

Eccentric

6 (20.6%)

Laboratory results at admission
Hemoglobin (g/dL)

12.9 ± 2.09

Creatinine (mg/dL)

1.19 ± 0.3

Low- density lipoprotein (mg/dL)

85.6 ± 23.3

proBNP, pg/mL (median)

14338

Data: mean ± SD. proBNP = pro-B-type natriuretic peptide.

dose (5–10 mcg/kg/min) for four patients. One patient
received high-dose dopamine (>10 mcg/kg/min) at the day
of admission. The doses were titrated according to patient
responses (Table 2 shows the difference of medication
between on admission and at discharge)
Six patients died during follow-up. Pump failure was
the cause of death in three patients. Acute renal failure
resulted in death in two patients and one patient died of
septic shock due to catheter infection. Median New York
Heart Association (NYHA) class was IV at baseline, and
it improved to class III after treatment. There was an
average weight loss of 5.8 ± 1.6 kg/participant. Thyroid
function, hepatic enzymes, and the blood glucose levels
of the patients were in the normal range, and the mean
hemoglobin level was 12.9 ± 2.09 g/dL. The mean SBP was
112.9 ± 12.3 mmHg at admission and 110 ± 13.8 mmHg
at the discharge (P = 0.023). The mean DBP was 67.3 ± 5.4
mmHg at admission and 66 ± 6.1 mmHg at the conclusion
of the therapy (P = 0.225). The average iv furosemide dose
was 63.4 ± 19.04 mg/day, and the median (interquartile
range) proBNP level was 14,338 pg/mL (6068–35,000 pg/
mL), which decreased after medical therapy (8819 pg/mL).
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One-quarter of the patients who had severe MR at
baseline were diagnosed with moderate MR after therapy
(Figure 1). Between the initiation and the conclusion of
the therapy, there were significant reductions in EROA
(0.36 ± 0.09 cm2 to 0.29 ± 0.09 cm2, P < 0.001), VC (0.57 ±
0.14 cm to 0.52 ± 0.15 cm, P < 0.001), RV (53.2 ± 18.4 mL
to 34.3 ± 11.5 mL, P < 0.001), left ventricular dimensions,
and sPAP (61.5 ± 12.2 mmHg to 51.1 ± 7.9 mmHg, P <
0.001) (Table 3, Figure 2). The ejection fraction increased
from 29.4 ± 7.8 % prior to therapy to 31.08 ± 7.2 % after
therapy (P < 0.001). There were not significant differences
in the changes of echocardiographic parameters between
patients who did and did not receive IV inotrope therapy.
In addition, we have found a significant positive
correlation between the decrease in proBNP level and the
reduction in EROA (r = 0.447, P = 0.032). However, there
was no correlation between the decrease in proBNP level
and the reduction in RV, and vena contracta (r = 0.167,
P = 0.447 and r = 0.027, P = 0.904, respectively). In an
investigation of the relationship between the weight loss
of the patients and alteration of EROA, RV and vena
contracta, there was no correlation between weight loss
and these parameters (r = 0.124, P = 0.573; r = 0.210, P =
0.336 and r = 0.401, P = 0.058, respectively) (Table 4).
4. Discussion
This study of the patients with advanced HF, who had
moderate or severe MR, demonstrated that volume
reduction with diuretics, as evidenced by a decline in
proBNP levels, was accompanied by a marked reduction
in EROA, vena contracta, and RV. This reduction in
MR severity appeared to result from a decrease in left
ventricular end-diastolic dimensions consistent with a
decrease in volume load on the left atrium and left ventricle.
Furthermore, the elimination of volume overload with
therapy resulted in a substantial decrease in sPAP, but no
significant change in blood pressure.
In HF, progressive LV dilation and remodeling
culminate in impairment of leaflet coaptation and
decreased valvular closing forces, resulting in secondary
MR [5]. These pathologic changes are dependent on
loading conditions. Secondary MR is, therefore, dynamic
in nature [7]. The hemodynamic effects of exercise and
various inotropic and vasodilator agents in patients
with secondary MR have been studied [17, 18]. In an
earlier study, Keren et al. looked at patients with severe
congestive HF and showed that isometric exercise resulted
in an increase in MR volume. They also revealed that both
nitroglycerin and dobutamine therapy led to a reduction
in MR in which mitral insufficiency was greatest [17].
Subsequent studies have described distinctive responses
to nitroprusside and dobutamine therapy. Nitroprusside
resulted in a reduction in MR, and dobutamine led to

SAVAŞ et al. / Turk J Med Sci
Table 2. The difference in medication between admission and discharge.
Medication

On admission, n (%)

At discharge, n (%)

Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker

14 (48.2%)

20 (68.9%)

β-blocker

16 (55.1%)

22 (75.8%)

Digoxin

4 (13.7%)

7 (24.1%)

Aspirin

16 (55.1%)

14 (48.2%)

Warfarin

5 (17.2%)

10 (34.4%)

Aldosterone antagonist

10 (34.4%)

16 (55.1%)

Furosemide

20 (68.9%)

21 (72.4%)

IV inotrope therapy
Dobutamine
Dopamine

14 (48.2%)
9 (31%)
5 (17.2%)

-

Figure 1. MR severity evaluated by transthoracic
echocardiography at baseline and after therapy. MR severity
compared from baseline to the last visit with an average length of
hospital stay of 10.9 ± 5.9 days. Results are matched and presented
for patients who did not die; data are given in percentage.

improved cardiac output with a variable effect on the degree
of MR in color Doppler echocardiography [2,19]. These
conflicting results could be attributed to the inclusion of
different causes of MR. Studies including patients who had
a diseased mitral valve apparatus such as rheumatic heart
disease or mitral annular calcification, might fail to show
the benefit of vasodilator therapy because these patients
are thought to have a fixed orifice, whereas patients with
MR caused by dilated cardiomyopathy, by contrast, are
thought to have a dynamic orifice [5].
Although prior studies have described a recovery in
the color jet area of MR and EROA in patients treated with
vasoactive drugs, which produced a reduction in afterload
[17, 18], the present study is the first to examine the
relationship of changes in volume load and MR severity,
while monitoring proBNP levels. More precisely, our study

evaluates the magnitude of this change by using quantitative
parameters of MR. The decrease in VC, RV, and EROA was
not associated with any significant changes in the SBP. A
significant relationship was found between the decrease in
proBNP levels and the reduction in EROA. However, an
optimal cut-off point of proBNP for predicting alterations
of EROA could not be identified because of the limited
number of patients recruited for the study whose proBNP
levels were heterogeneous. Use of proBNP levels to predict
a decrease in alteration of EROA, VC, and RV in patients
with HF remains unproven and further studies with large
sample sizes are needed to clarify this issue.
Reduction of MR is likely to be predominantly
related to improvement in the leaflet coaptation at lower
left ventricular volumes. In addition, a reduction in
left ventricular volumes may improve the relationship
between the subvalvular apparatus and valve leaflets
while also decreasing ischemia in patients who have
coronary artery disease. Indeed, it is difficult to determine
the relative contributions of changes in the annulus
and the subvalvular apparatus to this effect because the
mechanisms underlying MR are complex [5].
One of the remarkable findings of the present study is
that LVEF increased significantly after heart failure therapy.
This recovery would necessarily suggest that LV unloading
might lessen sphericity; intrinsic contractility and
especially cardiac mechanics have been restored; protein
expression has been normalized; and the neurohormonal
activation has been interrupted [20]. Previous studies
also revealed an improvement in left ventricular ejection
fraction among patients with HF after medical therapy
[21–23]. Moreover, Maurer et al. reported both a decrease
in heart rate and an improvement in chamber contractility
associated with beta blocker therapy within 2 weeks in
patients with HF, and these parameters were found to be
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Table 3. The difference in echocardiographic and laboratory measurements between the initiation and
conclusion of the therapy.
Measures

Pretreatment

Posttreatment

P-values

LVEDD, cm

6.42 ± 0.7

6.2 ± 0.6

<0.001

LVESD, cm

5.1 ± 0.7

4.9 ± 0.6

<0.001

EF %

29.4 ± 7.8

31.08 ± 7.2

<0.001

sPAP, mmHg

61.5 ± 12.2

51.1 ± 7.9

<0.001

EROA, cm2

0.36 ± 0.09

0.29 ± 0.09

<0.001

Vena contracta, cm

0.57 ± 0.14

0.52 ± 0.15

<0.001

RV, mL

53.2 ± 18.4

34.3 ± 11.5

<0.001

proBNP, pg/mL ,median [25%–75%]

14338 [12690-19202]

8819 [4120-12405]

<0.001

Creatinine, mg/dL

1.19 ± 0.3

1.33 ± 0.2

0.016

Echocardiography

Laboratory

Data are mean ± SD. proBNP values are presented as the median and 25%–75% quartile.
LVEDD = Left ventricle end-diastolic diameter; LVESD = Left ventricle end systolic diameter; EF =
Ejection fraction; sPAP = Systolic pulmonary artery pressure; EROA = Effective regurgitant orifice area;
RV = Regurgitant volume; proBNP = pro-B-type natriuretic peptide.

Figure 2. Individual values for effective regurgitant orifice area (EROA), vena contracta, regurgitant volume and ejection
fraction at baseline and after the therapy. Results are matched and presented for patients who did not die.
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Table 4. The correlation analyses between the changes in volume
status and echocardiographic measures of mitral regurgitation
severity.
Measurements

EROA

RV

Vena contracta

proBNP, pg/mL

r = 0.447
P = 0.032

r = 0.167
P = 0.447

r = 0.027
P = 0.904

Weight loss in kg

r = 0.124
P = 0.573

r = 0.210
P = 0.336

r = 0.401
P = 0.058

EROA = Effective regurgitant orifice area; RV = Regurgitant
volume; proBNP = pro-B-type natriuretic peptide.

the primary factors contributing to the increase in ejection
fraction [23].
The incidence of HF increases with age, and thus the
number of patients with HF who have MR, requiring
hospitalization or intervention will rise sharply in the next
decades [24,25]. Recently, interventional approaches to
MR in patients with left ventricular dysfunction have been
shown to have a potential role. MitraClip therapy (involves
a significant average cost) for secondary MR can improve
symptoms, functional capacity, quality of life, and may
induce reverse LV remodeling in high-risk patients, who
otherwise would have limited therapeutic options [26–27].

Thus, the correct evaluation of secondary MR severity is
quite important. Overestimating the MR carries all the risks
of aggressive treatment and involves high financial cost. In
our study population, one-quarter of the patients who had
severe MR at baseline were diagnosed as having moderate
MR after therapy. Therefore, we recommend that volume
status should be considered when making the diagnosis of
severe MR.
Limitations: The major limitation of this study is the
small sample size. The calculation of mitral regurgitant flow
makes several assumptions regarding a round regurgitant
orifice and in the technique of the proximal isovelocity
surface area as previously described [16]. Heart failure
therapy was not randomized and it would not be possible
to attribute the effects to a specific drug. Our findings may
not apply to patients with other etiologies of MR, such as
rheumatic valvular disease.
In conclusion, the present results demonstrated that
volume reduction, as evidenced by a decline in proBNP
levels, was accompanied by a marked reduction in EROA,
vena contracta, and RV in patients with left ventricular
dysfunction. Therefore, volume status should also be
considered when making decisions about interventional
approaches in these patients. Further studies are needed
with larger sample sizes to verify this issue.
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